Thus, all patients reconstituted their immune system with a median time of neutropenia of 5.5 days which is less than melanoma patients without pretreatment with ipilimumab but with high dosis IL-2 [28, 29], and less than our previous trial in ovarian cancer patients, also with high dose IL-2, where the median time of neutropenia was 9 days (range: 8–10) [18]. The gene discussed is IL2; the disease is ovarian carcinoma.